Drug Trial Radar · NCT00203060
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
Last checked: Nov 20, 2026Latest source record: Apr 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
404
Actual
Start
Jul 1997
Primary completion
Jul 2000
Study completion Jul 2000
Sponsor
- Lead sponsor
- Teva Neuroscience, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.
Conditions
- Parkinson's Disease
Interventions
Rasagiline MesylateDrug
tablet, 1 or 2 mg, daily, 58 weeks
placeboDrug
tablet, once daily, 58 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective is to assess the safety and efficacy of rasagiline in PD subjects, not receiving or requiring carbidopa/levodopa therapy. The primary efficacy measure will be the change in total UPDRS score, calculated from baseline to 26 weeks.Time frame: 58 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.